Is the Hype About Cannabis Nothing but Hype?
05 Jun 2017
Both Federal and State Governments have been very active recently in facilitating the use of cannabis in Australia, however, doctors do not appear to be showing the same level of interest.
The first two commercial shipments of medicinal cannabis products to be legally imported to Australia arrived in Melbourne and Perth on 3 May 2017, following action taken by the Federal Government.
On a State level, the NSW Government is rapidly expanding the number of hospitals involved in a medicinal cannabis trial for the prevention of chemotherapy-induced nausea and vomiting using new generation anti-emetics alongside cannabis products.
However, at a doctor level, there does not appear to be the same level of interest. Officials from the Federal Ministry of Health told the Community Affairs Legislation Committee on 29 May 2017 that there were only 25 authorised prescribers of medicinal cannabis products. All but one of the 25 authorised prescribers are paediatric neurologists treating epilepsy in children. There are a further 66 doctors who have been allowed to prescribe through the Special Access Scheme (for a single patient).
The low number of authorised prescribers could be explained by the incomplete evidence base for the medical use of cannabis.
The October 2016 RACGP position paper reported that there remains much to be learned, particularly relating to treatment efficacy and the longer term side-effects of cannabis-based drugs. The RACGP concluded that there is very little high quality evidence for the medical use of cannabis.
The current Queensland guidelines stress that medicinal cannabis is not considered first line therapy for any indication, and should be considered only where conventional treatments have been tried and proven unsuccessful in managing the patient’s symptoms.
A study published in JAMA on 25 May 2017 by Australian researchers revealed that among patients with Dravet syndrome (a complex childhood epilepsy disorder associated with drug-resistant seizures and a high mortality rate) cannabidiol resulted in a greater reduction in convulsive-seizure frequency than placebo and was associated with higher rates of adverse events.
There is a complex regulatory process for doctors to navigate if they plan to prescribe medicinal cannabis.
This blog contains general information only. We recommend you contact your medical defence organisation or insurer when you require specific advice in relation to medico-legal matters.
Doctors Let's Talk: Get Yourself A Fricking GP
Get yourself a fricking GP stat! is a conversation with Dr Lam, 2019 RACGP National General Practitioner of the Year, rural GP and GP Anesthetics trainee, that explores the importance of finding your own GP as a Junior Doctor.
25 Oct 2022
Systematic efforts to reduce harms due to prescribed opioids – webinar recording
Efforts are underway across the healthcare system to reduce harms caused by pharmaceutical opioids. This 43-min recording of a live webinar, delivered 11 March 2021, is an opportunity for prescribers to check, and potentially improve, their contribution to these endeavours. Hear from an expert panel about recent opioid reforms by the Therapeutic Goods Administration and changes to the Pharmaceutical Benefits Scheme.
14 May 2021
Diplomacy in a hierarchy: tips for approaching a difficult conversation
Have you found yourself wondering how to broach a tough topic of conversation? It can be challenging to effectively navigate a disagreement with a co-worker, especially if they're 'above' you; however, it's vital for positive team dynamics and safe patient care. In this recording of a live webinar you'll have the opportunity to learn from colleagues' experiences around difficult discussions and hear from a diverse panel moderated by Dr Kiely Kim (medico-legal adviser and general practitioner). Recorded live on 2 September 2020.
05 Oct 2020
